Prevalence of Extended-Spectrum Beta-Lactamases in Enterobacteriaceae, <i>Pseudomonas </i>and <i>Stenotrophomonas</i> as Determined by the VITEK 2 and E Test Systems in a Kuwait Teaching Hospital

Vol. 14, No. 5, 2005

View or print article as PDF (263 KB)

Journal Home

Medline Abstract (ID 16103698)

Medline Related Articles

Download Citation

Original Paper

Prevalence of Extended-Spectrum Beta-Lactamases in Enterobacteriaceae, Pseudomonas and Stenotrophomonas as Determined by the VITEK 2 and E Test Systems in a Kuwait Teaching Hospital
Wafaa Jamal^a, V.O. Rotimi^a-c, Fatima Khodakhast^b, Rolla Saleem^a, Aleyamma Pazhoor^a, Ghyada Al Hashim^c

^aDivision of Microbiology, Mubarak Al-Kabeer Hospital, and
^bDepartment of Microbiology, Faculty of Medicine, Kuwait University, and
^cInfection Control Unit, Mubarak Hospital, Kuwait

Address of Corresponding Author

Med Princ Pract 2005;14:325-331 (DOI: 10.1159/000086930)

Key Words

Prevalence
Extended-spectrum -lactamases
VITEK 2
E test

Abstract

Objective: To determine the prevalence of extended-spectrum beta -lactamase (ESBL)-producing members of the Enterobacteriaceae using VITEK 2 and E test systems. Materials and Methods: A total of 3,592 consecutive gram-negative isolates (single isolate per patient) of the family of Enterobacteriaceae and Pseudomonas adjudged to be clinically relevant to the patient's infection were studied for ESBL production over a period of 1 year at Mubarak Al-Kabeer Hospital, Kuwait. Two methods were used: the automated VITEK 2 system and E test ESBL, a manually manipulated plastic strip containing various gradients of beta -lactam antibiotics. These tests and interpretative criteria for the results were performed according to the manufacturer's instructions. Results: Of the 3,592 bacterial isolates, 264 (7.5%) and 185 (5.2%) were positive for ESBL production by the VITEK 2 and E test, respectively. All the ESBL-producing Pseudomonas aeruginosa identified by VITEK 2 gave indeterminate results by E test. Prevalent ESBL producers, identified by the VITEK 2 versus E test, respectively, were: Citrobacter spp. (15 vs. 3.2%), K. pneumoniae (12.2 vs. 11.4%), Enterobacter spp. (12 vs. 3%), E. coli (6.5 vs. 5.6%), P. aeruginosa (6.5 vs. 0%) and Morganella spp. (2 vs. 1%). The most common infection associated with ESBL-producing pathogens was urinary tract infection (68.2%), followed by wound infection (14.4%) and bloodstream infection (6.1%). Conclusion: The result of this study showed a relatively high prevalence of clinically significant ESBL producers among the Enterobacteriaceae and Pseudomonas spp. at our teaching hospital. The VITEK 2 identified a higher prevalence of ESBL strains than the E test.

References

1.: Livermore DM: Bacterial resistance: origin, epidemiology, and impact. Clin Infect Dis 2003;36(suppl 1):11-23.
2.: Livermore DM: -Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-584.
3.: Nordmann P, Guibert M: Extended-spectrum -lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother 1998;42:128-131.
4.: Poirel L, Rotimi VO, Mokaddas EM, Karim A, Nordmann P: VEB-1 like extended spectrum beta-lactamases in Pseudomonas aeruginosa, Kuwait. Emerg Infect Dis 2001;7:468-470.
5.: Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA: Multiple-antibiotic resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:517-523.
6.: Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO: Extended spectrum -lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-1171.
7.: Schiappa DA, Hayden MK, Matushek MG, Hashemi FN, Sullivan J, Smith KY, Miyashiro D, Quinn JP, Weinstein RA, Trenholme GM: Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996;174:529-936.
8.: Paterson DL, Ko W-C, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL: Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended spectrum -lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-2212.
9.: Canton R, Perez-Vazquez M, Oliver A, Coque TM, Loza E, Ponz F, Baquero F: Validation of VITEK-2 and the Advanced Expert System with a collection of Enterobacteriaceae harbouring extended spectrum or inhibitor resistant beta-lactamases. Diagn Microbiol Infect Dis 2001;41:65-70.
10.: Sanders CC, Peyret M, Moland ES, Shubert C, Thomson KS, Boeufgras JM, Sanders WE Jr: Ability of VITEK 2 Advanced Expert System to identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol 2000;38:570-574.
11.: Sanders CC, Peyret M, Moland ES, Cavalieri SJ, Shubert C, Thomson KS, Boeufgras JM, Sanders WE: Potential impact on VITEK 2 system and Advanced Expert System on the clinical laboratory of a university-based hospital. J Clin Microbiol 2001;39:2379-2385.
12.: Bush K: Is it important to identify extended-spectrum beta-lactamase producing isolates? Eur J Clin Microbiol Infect Dis 1996;15:361-364.
13.: Hsueh PR, Liu YC, Yang D, Yan JJ, Wu TL, Huang WK, Wu JJ, Ko WC, Leu HS, Yu CR, Luh KT: Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb Drug Resist 2001;7:373-382.
14.: Tzelepi E, Giakkoupi P, Sofianou D, Loukova V, Kemeroglou A, Tsakris A: Detection of extended-spectrum -lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol 2000;38:542-546.
15.: Bradford PA, Yang Y, Sahm D, Grope I, Gardovska D, Storch G: CTX-M-5, a novel cefotaxime-hydrolyzing -lactamase from an outbreak of Salmonella typhimurium in Latvia. Antimicrob Agents Chemother 1998;42:1980-1984.
16.: Shannon K, French G: Multiple-antibiotic-resistant Salmonella. Lancet 1998;352:490.
17.: Tassios PT, Gazouli M, Tzelepi E, Milch H, Kozlova N, Sidorenko S, Legakis NJ, Tzouvelekis LS: Spread of Salmonella typhimurium clone resistant to expanded spectrum cephalosporins in three European countries. J Clin Microbiol 1999;37:3774-3777.
18.: Mirza S, Kariuki S, Muman KZ, Beeching NJ, Hart CA: Analysis of plasmid and chromosomal DNA of multidrug resistant Salmonella enterica Serovar typhi from Asia. J Clin Microbiol 2000;38:1449-1452.
19.: Saurina G, Quale JM, Manikal VM, Oydna E, Landam D: Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother 2000;45:895-898.
20.: De Champs C, Sirot D, Chanal C, Bonnet J: A 1998 survey of extended spectrum -lactamases in Enterobacteriaeae in France: the French study Group. Antimicrob Agents Chemother 2000;44:3177-3179.
21.: Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G: The Italian ESBL Study Group: Occurrence of extended-spectrum -lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to -lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002;46:196-202.
22.: Stobberingh EE, Arends J, Hoogkamp-Korstanje JA, Goessens WH, Visser MR, Buiting AG, Debets-Ossenkopp YJ, van Ketel RJ, van Ogtrop ML, Sabbe LJ, Voorn GP, Winter HL, van Zeijl JH: Occurrence of extended spectrum beta-lactamases (ESBL) in Dutch hospitals. Infection 1999;27:348-354.
23.: Vercauteren E, Descheemaeker P, Ieven M, Sanders CC, Goossens H: Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital. J Clin Microbiol 1997;35:2191-2197.
24.: Palucha A, Mikiewicz B, Hryniewicz W, Gniadkowski M: Concurrent outbreaks of extended-spectrum -lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospital. J Antimicrob Chemother 1999;44:489-499.
25.: Brown DFJ, Wattam Walpole E: Detection of extended spectrum beta lactamases (ESBLs) with E-test ESBL strip. Abstracts, 35th Intersci Conf on Antimicrob Agents and Chemother, American Society for Microbiology, Washington, 1995.
26.: Harrel LJ, Thorpe JJ, McDonald LC, Reller LB: Analysis of suspected extended spectrum beta-lactamase (ESBL)-producing Klebsiella spp by the new E-test ESBL strip, double disk diffusion test and pulsed field electrophoresis (PFGE). Abstracts, 35th Intersci Conf on Antimicrob Agents and Chemother, Washington, 1995.
27.: Leverstein-van Hall MA, Fluit AC, Paauw A, Box AT, Brisse S, Verhoef J: Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1 and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp. J Clin Microbiol 2002;40:3703-3711.
28.: Cormican MG, Marshall SA, Jones RN: Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by E test ESBL screen. J Clin Microbiol 1996;34:1880-1884.
29.: Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-358.
30.: Lucet JC, Chevret S, Decre D, Vanjak D, Macrez A, Bedos JP, Wolff M, Regnier B: Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996;22:430-436.
31.: Karas JA, Pillay DG, Muckart D, Sturm AW: Treatment failure due to extended spectrum -lactamase. J Antimicrob Chemother 1996;37:203-204.
32.: Gniadkowski M: Evolution and epidemi ology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001;7:597-608.

Author Contacts

Prof. V.O. Rotimi
Consultant/Head of Clinical Microbiology Unit, Department of Microbiology
Faculty of Medicine, Kuwait University, PO Box 24923
13110 Safat (Kuwait)
Tel. +965 531 2300, ext. 6509, Fax +965 533 2719, E-Mail Vincent@hsc.edu.kw

Article Information

Received: March 16, 2004
Revised: June 20, 2004
Number of Print Pages : 7
Number of Figures : 2, Number of Tables : 3, Number of References : 32

Publication Details

Medical Principles and Practice (International Journal of the Kuwait University Health Sciences Centre)

Vol. 14, No. 5, Year 2005 (Cover Date: September-October 2005)

Journal Editor: Al Awadi, F. (Kuwait)
ISSN: 1011-7571 (print), 1423-0151 (Online)

For additional information: http://www.karger.com/mpp

Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.

	© 2009 S. Karger AG, Basel
	Last update: 12/8/2005